Free tool
FAERS Monitor: Braftovi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210496 or its brand name (Braftovi, Encorafenib). Reports on generic versions are filed under their own applications.
Reports
10,191
Serious
7,170
70% of reports
Hospitalization
2,833
Death reported
1,700
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,201
- off label use1,142
- nausea872
- fatigue795
- diarrhoea652
- pyrexia615
- neoplasm progression553
- product use in unapproved indication523
- vomiting488
- rash486
- serous retinal detachment360
- arthralgia329
- decreased appetite320
- malaise306
- malignant neoplasm progression280
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 245 |
| 2019 | 1,312 |
| 2020 | 1,380 |
| 2021 | 1,146 |
| 2022 | 1,327 |
| 2023 | 1,390 |
| 2024 | 1,218 |
| 2025 | 1,239 |
| 2026 | 933 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,968 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| serous retinal detachmentSignal | 360 | 1555.2 | 1358.3 | 318,069 |
| neoplasm progressionSignal | 553 | 33.3 | 30.7 | 17,071 |
| malignant neoplasm progressionSignal | 280 | 5.7 | 5.0 | 1,071 |
| product use in unapproved indicationSignal | 523 | 4.4 | 4.0 | 1,365 |
| pyrexiaSignal | 615 | 3.7 | 3.4 | 1,211 |
| deathSignal | 1,201 | 2.9 | 2.7 | 1,532 |
| decreased appetiteSignal | 320 | 2.8 | 2.6 | 385 |
| off label useSignal | 1,142 | 2.7 | 2.6 | 1,266 |
| rashSignal | 486 | 2.3 | 2.1 | 364 |
| nauseaSignal | 872 | 2.3 | 2.1 | 646 |
| vomitingSignal | 488 | 2.1 | 2.0 | 303 |
| fatigueSignal | 795 | 2.1 | 2.0 | 480 |
| diarrhoeaSignal | 652 | 2.1 | 1.9 | 379 |
| arthralgia | 329 | 1.6 | 1.5 | 82 |
| malaise | 306 | 1.4 | 1.3 | 42 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.